Download presentation
Presentation is loading. Please wait.
Published byHarvey Sullivan Modified over 5 years ago
1
Cost-effectiveness of FDG-PET for staging non–small cell lung cancer: a decision analysis
Walter J. Scott, MD, James Shepherd, MS, Sanjiv Sam Gambhir, MD, PhD The Annals of Thoracic Surgery Volume 66, Issue 6, Pages (December 1998) DOI: /S (98)
2
Fig 1 Decision tree showing the four strategies analyzed (A to D). Square represents a decision node; circles are chance nodes; and triangles are terminal nodes. (Bx = biopsy; CT = computed tomography; NSCLC = non–small cell lung carcinoma; PET = positron emission tomography.) The Annals of Thoracic Surgery , DOI: ( /S (98) )
3
Fig 2 Incremental cost-effectiveness ratio (ICER) analysis over a range of positron emission tomography (PET) Medicare reimbursement values with CT plus PET strategies (B to D) compared with the baseline strategy A. Alternative strategies with a negative ICER dominate strategy A. Horizontal line marks $50,000 per life-year saved, the threshold value below which an alternative strategy is considered to be cost-effective. The Annals of Thoracic Surgery , DOI: ( /S (98) )
4
Fig 3 Incremental cost-effectiveness ratio (ICER) analysis over a range of prevalence values for metastasis with CT plus PET strategies (B to D) compared with the baseline strategy A. Horizontal line as in Figure 2. The Annals of Thoracic Surgery , DOI: ( /S (98) )
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.